Halozyme Therapeutics (HALO) said late Thursday the US Food and Drug Administration approved Swiss healthcare company Roche's cancer immunotherapy, Tecentriq Hybreza, in combination with Halozyme's Enhanze drug delivery technology.
The product is a combination of the atezolizumab antibody and Halozyme's human hyaluronidase enzyme, rHuPH20.
The product will be available in the US for adults with certain types of lung, liver, skin and soft tissue cancer.
Price: 60.00, Change: -0.54, Percent Change: -0.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments